December 2018 - Page 312 of 313

NYSE Companies - December 2, 2018

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies

Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in […]

NASDAQ Companies - December 2, 2018

Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome

Data Presented During Late-Breaker Session at 72nd American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, […]

NASDAQ Companies - December 1, 2018

Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting

CAMBRIDGE, Mass., Dec. 01, 2018 (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing […]

NASDAQ Companies - December 1, 2018

Verizon offering free calling, text and data for customers impacted by Alaska earthquake

ANCHORAGE, Ala., Dec. 01, 2018 (GLOBE NEWSWIRE) — For our customers impacted by the earthquake that struck Alaska on November […]

NASDAQ Companies - December 1, 2018

BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting

Company to Host Investor Meeting and Webcast on Monday, December 3, at 8 pm PST CAMBRIDGE, Mass. and BEIJING, China, […]

NYSE Companies - December 1, 2018

Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers

In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r […]

NASDAQ Companies - December 1, 2018

Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant

Experience to date in clinical study shows high clinical response rates for patients with visceral GvHD or GvHD that was […]

NASDAQ Companies - December 1, 2018

Nasdaq Announces the Closure of its U.S. Markets in Honor of a National Day of Mourning for President George H.W. Bush

NEW YORK, Dec. 01, 2018 (GLOBE NEWSWIRE) — Nasdaq announces that it will observe the passing of President George H.W. […]

NASDAQ Companies - December 1, 2018

Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting

— 29.6% Overall Response Rate Including 9.6% Complete Response Rate — — Amongst the Patients with Complete or Partial Response, Median Duration […]

NASDAQ Companies - December 1, 2018

Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018

Interim results suggest rivo-cel outcomes were comparable to a control study of transplants from matched unrelated donors, a requirement for […]